Conditions: Polycystic Ovarian Syndrome Vitamin D Deficiency
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 36
Healthy volunteers: no

Brief summary:
The investigators conducted a prospective un-blinded pilot study of Vitamin D plus Calcium (Ca) supplementation in overweight (BMI \> 27) premenopausal women diagnosed with Polycystic Ovarian Syndrome (PCOS), as defined by the Rotterdam Criteria, 2003, and who were deficient in vitamin D as reflected by serum 25-hydroxy (25-OH) vitamin D (serum levels \< 20 ng/mL).

Detailed description:
We had hypothesized that in women with PCOS, administering optimal daily doses of vitamin D3, as recommended by the National Academy of Sciences, 2000IU Cholecalciferol and 1000mg of calcium, both per oral (PO), over a three month period will improve their metabolic picture, and possibly hormone profile.

Over the course of the trial, after the first 5 subjects had completed 3 month intervention,we observed that daily 2000IU D3 dosing regime was inadequate in normalizing vitamin D status in the study population; the dosing regimen was therefore modified to include weekly supplementation with 50,000IU D2 in addition to daily dosing with 2000IU D3.

Arms:
arm 1: None

Interventions: intervention 1: Vitamin D2 (Ergocalciferol) intervention 2: Medroxyprogesterone (Provera) intervention 3: Vitamin D3 (Cholecalciferol) intervention 4: Elemental Calcium
Intervention descriptions: intervention 1: 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months) intervention 2: 10mg, PO, daily for ten days intervention 3: 2,000IU (or 2 tablets), PO, daily (supplements taken for three months) intervention 4: 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)

Protocol document: